HUTCHMED Announces Marketing Approval For ELUNATE By Pharmacy And Poisons Board Of Hong Kong
HUTCHMED China (?HCM) announced marketing approval of ELUNATE, or fruquintinib by the Pharmacy and Poisons Board of Hong Kong for the treatment of adult patients with previously treated metastatic colorectal cancer.